Concurrent Investment Advisors LLC Has $2.41 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Concurrent Investment Advisors LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 52.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 14,765 shares of the company’s stock after buying an additional 5,091 shares during the period. Concurrent Investment Advisors LLC’s holdings in Zoetis were worth $2,406,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Ownership Capital B.V. grew its stake in Zoetis by 10.0% in the 4th quarter. Ownership Capital B.V. now owns 848,978 shares of the company’s stock valued at $138,324,000 after buying an additional 77,360 shares during the last quarter. Cumberland Partners Ltd acquired a new position in shares of Zoetis during the 4th quarter worth approximately $1,499,000. Ieq Capital LLC grew its position in shares of Zoetis by 1.3% during the 4th quarter. Ieq Capital LLC now owns 27,377 shares of the company’s stock worth $4,461,000 after purchasing an additional 344 shares in the last quarter. Private Advisor Group LLC grew its position in shares of Zoetis by 2.3% during the 4th quarter. Private Advisor Group LLC now owns 29,149 shares of the company’s stock worth $4,749,000 after purchasing an additional 654 shares in the last quarter. Finally, Bryn Mawr Capital Management LLC grew its position in shares of Zoetis by 25.0% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 20,902 shares of the company’s stock worth $3,406,000 after purchasing an additional 4,178 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZTS. Piper Sandler decreased their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Morgan Stanley decreased their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $214.90.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Zoetis Price Performance

ZTS stock opened at $160.39 on Friday. The company has a fifty day moving average price of $166.51 and a 200-day moving average price of $178.04. The company has a market capitalization of $71.82 billion, a P/E ratio of 29.32, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.